New pneumonia vaccine for immunocompromised elderly veterans
Part of Immune system & allergy, Infections clinical trials.
This trial is testing a new pneumonia vaccine (called PCV21) in older veterans with weakened immune systems who have already had an older pneumonia shot (PPSV23). It aims to see if the new vaccine can offer better protection against pneumonia and related infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a condition that weakens the immune system, like kidney disease, diabetes, cancer, or HIV.
- You have had a type of pneumonia vaccine called PPSV23 in the past.
- It has been at least 5 years since that last PPSV23 shot.
- You have not taken antibiotics in the last 90 days.
- You have not had certain other pneumonia vaccines (PCV13, PCV15, or PCV20) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pneumonia vaccine (PCV13) in healthy infants to see if it works as well as a current vaccine. It compares the immune response and safety of the two vaccines.
This study tests a new vaccine that protects against 21 types of bacteria that cause pneumonia and other infections. It is for healthy infants around 2 months old to see if it works as well as the current vaccine.
This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.
This trial tests a new vaccine (called PCV26) in people 60 and older. The goal is to see if the vaccine is safe and to gather early information on how it works.
This trial tests a new vaccine designed to protect against 24 types of pneumococcal bacteria (which cause pneumonia and other serious infections). Researchers are checking if it's safe and how well it works in infants, children, and adults.
This study tests a new pneumococcal vaccine (PCV15) to see how well it protects against carrying the bacteria that can cause pneumonia. Healthy adults aged 18–50 who have not had a pneumococcal vaccine in the last 5 years may join.
Hear when a new Pneumococcal Vaccines trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.